Himalayas-1 randomizes 1:1 to rinzimetostat 400 mg daily plus darolutamide vs physician’s choice ARPI or docetaxel in mCRPC progressing after abiraterone. Radiographic PFS is the primary end point, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results